Devices/Safety Alert·openFDA/device

BIPAP S/T C SERIES (RESPIRONICS, INC.) — Malfunction

MediumPublished Jun 30, 2026· AI-analyzed Jul 14, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

A malfunction was reported involving the BIPAP S/T C SERIES manufactured by RESPIRONICS, INC. The source does not specify the exact nature or physiological consequences of the malfunction.

Who it affects

This affects Respironics, Inc., users of the BIPAP S/T C SERIES, and medical device professionals involved in the management of respiratory therapy technology.

Why it matters

The reporting of a malfunction for a life-supporting or life-sustaining device category typically necessitates a thorough investigation into the root cause. This event suggests potential reliability issues that may require regulatory scrutiny, risk assessment updates, or corrective actions to ensure patient safety and maintain compliance with quality system regulations.

Practical takeaway

Regulatory and Quality teams should review internal complaint files for similar malfunctions in this product line. Ensure that post-market surveillance systems are capturing and reporting these events in accordance with 21 CFR 803 requirements. Verification of the CAPA process may be necessary if a trend is identified.

FDA source material

Event type: Malfunction. Device: BIPAP S/T C SERIES by RESPIRONICS, INC..

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.